



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



FHD-286

Item No. 41864

CAS Registry No.: 2671128-05-3
Formal Name: N-[(1S)-2-[[4-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-2-pyridinyl]-2-thiazolyl]amino]-1-(methoxymethyl)-2-oxoethyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide
MF: C₂₄H₃₀N₆O₆S₂
FW: 562.7
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FHD-286 is supplied as a solid. A stock solution may be made by dissolving the FHD-286 in the solvent of choice, which should be purged with an inert gas. FHD-286 is slightly soluble (0.1-1 mg/ml) in ethanol, acetonitrile, and DMSO

Description

FHD-286 is an inhibitor of Brahma homolog (BRM), also known as SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), and Brahma-related gene 1 (BRG1), also known as SMARCA4.¹ It induces differentiation of, and reduces viability in, MV4-11 and MOLM-13 acute myeloid leukemia (AML) cells, which express mixed-lineage leukemia 1 (MLL1) rearrangements, and OCI-AML-3 AML cells, which express mutant nucleophosmin 1 (NPM1), when used at a concentration of 30 nM. FHD-286 (100 nM) decreases BRG1-chromatin and BRM-chromatin associations in MOLM-13 cells. *In vivo*, FHD-286 (1.5 mg/kg) decreases tumor burden and increases survival in patient-derived xenograft (PDX) mouse models of AML when used alone or in combination with venetoclax (ABT-199; Item No. 16233), OTX015 (Item No. 15947), SNDX-5613 (Item No. 40758), or decitabine (Item No. 11166).

Reference

1. Fiskus, W., Piel, J., Collins, M., *et al.* BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. *Blood* **143**(20), 2059-2072 (2024).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/18/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM